← Leaderboards
Mitchell J Goldman
Indiana Univ-Purdue Univ At Indianapolis
$3,011,275
Attributed
$3,011,275
Total exposure
67
Grants
48
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $866.1K · FY2005–08$1M$750K$500K$250K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$3,011,275 · 67
By mechanism
M01$3,011,275 · 67
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- J. Dennis Fortenberry$13,386,579
- Mitchell Goldman$10,867,864
- Hal E. Broxmeyer$36,408,829
- Joan K Austin$6,480,296
- C. Conrad Johnston$0
Research focus
Computer Retrieval Of Information On Scientific Projects DatabaseUnited States National Institutes Of HealthSourceGrantResearch PersonnelInstitutionFundingResourcesWeekEnrollmentRandomizedSafetyEvaluationLaboratoriesClinical ResearchAntiretroviral TherapyLabelHuman Therapy EvaluationHiv InfectionsHuman SubjectVisitAids TherapyPatient Oriented ResearchPharmaceutical Preparations
Grant awards (74)
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) -$67,013
M01 · FY2008 · RR · contact PI
A PHASE III B, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITO$47,250
M01 · FY2008 · RR · contact PI
A MULTICENTER, OPEN-LABEL PHASE I/II STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY$21,581
M01 · FY2008 · RR · contact PI
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS (SOCA)$12,948
M01 · FY2008 · RR · contact PI
A MULTICENTER, OPEN-LABEL, CONTROLLED PHASE II STUDY TO EVALUATE SAFETY AND I$11,812
M01 · FY2008 · RR · contact PI
PHASE I B/IIA DOSE-FINDING SAFETY AND ACTIVITY STUDY OF AMD11070 (AN ORALLY$10,904
M01 · FY2008 · RR · contact PI
A RANDOMIZED STUDY OF TREATMENT WITH TENOFOVIR DF, EMTRICITABINE, AND LOPINAVIR$8,859
M01 · FY2008 · RR · contact PI
LOPINAVIR/RITONAVIR PLUS EFAVIRENZ VERSUS LOPINAVIR/RITONAVIR PLUS STAVUDINE$7,951
M01 · FY2008 · RR · contact PI
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN$7,723
M01 · FY2008 · RR · contact PI
A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE$6,815
M01 · FY2008 · RR · contact PI
COMPARE TWICE DAILY POTENT ANTIRETROVIRAL THERAPY$1,363
M01 · FY2008 · RR · contact PI
AZITHROMYCIN PROPHYLAXIS FOR PREVENTING MYCOBACTERIUM AVIUM COMPLEX(ACTG 362)$908
M01 · FY2008 · RR · contact PI
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP)$456
M01 · FY2008 · RR · contact PI
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS PRESENTING WITH ACUTE$455
M01 · FY2008 · RR · contact PI
SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS AMONG HIV-1-INFECTED$455
M01 · FY2008 · RR · contact PI
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) -$281,088
M01 · FY2007 · RR · contact PI
A PHASE III B, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITO$198,190
M01 · FY2007 · RR · contact PI
A MULTICENTER, OPEN-LABEL PHASE I/II STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY$90,521
M01 · FY2007 · RR · contact PI
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS (SOCA)$54,312
M01 · FY2007 · RR · contact PI
A MULTICENTER, OPEN-LABEL, CONTROLLED PHASE II STUDY TO EVALUATE SAFETY AND I$49,547
M01 · FY2007 · RR · contact PI
PHASE I B/IIA DOSE-FINDING SAFETY AND ACTIVITY STUDY OF AMD11070 (AN ORALLY$45,736
M01 · FY2007 · RR · contact PI
A RANDOMIZED STUDY OF TREATMENT WITH TENOFOVIR DF, EMTRICITABINE, AND LOPINAVIR$37,161
M01 · FY2007 · RR · contact PI
LOPINAVIR/RITONAVIR PLUS EFAVIRENZ VERSUS LOPINAVIR/RITONAVIR PLUS STAVUDINE$33,350
M01 · FY2007 · RR · contact PI
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN$32,395
M01 · FY2007 · RR · contact PI
A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE$28,585
M01 · FY2007 · RR · contact PI
COMPARE TWICE DAILY POTENT ANTIRETROVIRAL THERAPY$5,716
M01 · FY2007 · RR · contact PI
AZITHROMYCIN PROPHYLAXIS FOR PREVENTING MYCOBACTERIUM AVIUM COMPLEX(ACTG 362)$3,809
M01 · FY2007 · RR · contact PI
SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS AMONG HIV-1-INFECTED$1,907
M01 · FY2007 · RR · contact PI
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS PRESENTING WITH ACUTE$1,906
M01 · FY2007 · RR · contact PI
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP)$1,900
M01 · FY2007 · RR · contact PI
ADULT AIDS CLIN TRIAL GRP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) - A5001$190,784
M01 · FY2006 · RR · contact PI
LOPINAVIR/RITONAVIR PLUS EFAVIRENZ VERSUS LOPINAVIR/RITONAVIR PLUS STAVUDINE$156,428
M01 · FY2006 · RR · contact PI
COMPARE TWICE DAILY POTENT ANTIRETROVIRAL THERAPY$78,945
M01 · FY2006 · RR · contact PI
PHASE IB/IIA DOSE-FINDING SAFETY AND ACTIVITY STUDY OF AMD11070 (AN ORALLY$48,244
M01 · FY2006 · RR · contact PI
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS (SOCA)$42,396
M01 · FY2006 · RR · contact PI
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN$28,508
M01 · FY2006 · RR · contact PI
EFFECT OF IMMUNIZATION WITH THE MRK AD5 HIV-1 GAG VACCINE IN HIV INFECTED$22,659
M01 · FY2006 · RR · contact PI
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS PRESENTING WITH ACUTE$21,199
M01 · FY2006 · RR · contact PI
A RANDOMIZED STUDY OF TREATMENT WITH TENOFOVIR DF, EMTRICITABINE, AND LOPINAV$12,427
M01 · FY2006 · RR · contact PI
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE TRIAL OF A NOVEL CCR5 AN$9,502
M01 · FY2006 · RR · contact PI
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI$9,502
M01 · FY2006 · RR · contact PI
SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS AMONG HIV-1-INFECTED$8,772
M01 · FY2006 · RR · contact PI
A PHASE IIIB, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY AND EFF$6,579
M01 · FY2006 · RR · contact PI
PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF SCH 41$6,579
M01 · FY2006 · RR · contact PI
A MULTICENTER, OPEN-LABEL PHASE I/II STUDY TO EVALUATE SAFETY AND IMMUNOGENIC$5,116
M01 · FY2006 · RR · contact PI
AZITHROMYCIN PROPHYLAXIS FOR PREVENTING MYCOBACTERIUM AVIUM COMPLEX(ACTG 362)$4,386
M01 · FY2006 · RR · contact PI
PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS WITH CD4+ CELL$730
M01 · FY2006 · RR · contact PI
VALGANICLOVIR THERAPY FOR CMV AS DETECTED BY PLASMACMV DNA PCR ASSAY (5030)$202
M01 · FY2006 · RR · contact PI
LOPINAVIR/RITONAVIR PLUS EFAVIRENZ VERSUS LOPINAVIR/RITONAVIR PLUS STAVUDINE$297,103
M01 · FY2005 · RR
ADULT AIDS CLIN TRIAL GRP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) - A5001$210,513
M01 · FY2005 · RR
COMPARE TWICE DAILY POTENT ANTIRETROVIRAL THERAPY$88,177
M01 · FY2005 · RR
LONGITUDINAL STUDY OF OCULAR COMPLICATIONS OF AIDS (SOCA)$64,346
M01 · FY2005 · RR
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN$30,981
M01 · FY2005 · RR
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS PRESENTING WITH ACUTE$15,889
M01 · FY2005 · RR
PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF SCH 41$10,326
M01 · FY2005 · RR
CAPRAVIRINE IN COMBINATION WITH KALETRA$6,356
M01 · FY2005 · RR
PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS WITH CD4+ CELL$4,766
M01 · FY2005 · RR
A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE$3,177
M01 · FY2005 · RR
AZITHROMYCIN PROPHYLAXIS FOR PREVENTING MYCOBACTERIUM AVIUM COMPLEX(ACTG 362)$3,177
M01 · FY2005 · RR
SAFETY PROFILE OF GW433908 CONTAINING REGIMENS IN HIV1 INFECTED SUBJECTS$3,177
M01 · FY2005 · RR
A PHASE IIIB, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY AND EFF$794
M01 · FY2005 · RR
VALGANICLOVIR THERAPY FOR CMV AS DETECTED BY PLASMACMV DNA PCR ASSAY (5030)$663
M01 · FY2005 · RR
Adult Aids clin. trial grp longitudinal linked randomized trials (ALLRT) - A5001$186,562
M01 · FY2004 · RR
LOPINAVIR/RITONAVIR PLUS EFAVIRENZ VERSUS LOPINAVIR/RITONAVIR PLUS STAVUDINE$148,473
M01 · FY2004 · RR
Longitudinal Study of Ocular Complications of AIDS (SOCA)$71,516
M01 · FY2004 · RR
...COMPARE TWICE DAILY POTENT ANTIRETROVIRAL THERAPY$69,961
M01 · FY2004 · RR
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN$30,316
M01 · FY2004 · RR
ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS PRESENTING WITH ACUTE$11,660
M01 · FY2004 · RR
PREDICTORS OF IMMUNOLOGIC AND CLINICAL PROGRESSION IN SUBJECTS WITH CD4+ CELL$10,105
M01 · FY2004 · RR
ABILITY OF VACCINE INDUCED HELPER AND CTL RESPONSES TO CONTROL VIREMIA$6,996
M01 · FY2004 · RR
Azithromycin prophylaxis for preventing Mycobacterium Avium Complex(ACTG 362)$6,996
M01 · FY2004 · RR
Valganciclovir therapy for CMV as detected by plasmaCMV DNA PCR assay (5030)$1,495
M01 · FY2004 · RR
Trial to promote efficient control of viral replications (A5024)$1,399
M01 · FY2004 · RR
HIV-specific helper/CTL responses in pts on potent Antiretroviral Therapy:A5058$777
M01 · FY2004 · RR